Contract Deobligations Alert — August 09, 2026

SIGA's $626.5 million firm-fixed-price contract for smallpox antiviral drug development provides multi-year revenue visibility (~$56.9M/year), with $447.2 million already outlayed, indicating strong government commitment and cash flow.

The $209.2 million VA medical disability exam contract for Leidos' subsidiary QTC Medical Services was performed over one year (Oct 2020-Sep 2021) with $196.6 million already outlayed, meaning no forward revenue contribution remains from this award.

The sole-source, time-and-materials award to OUR RESCUE for legal support services has a short 6-month base period and high pricing risk, with no public financial data to assess the nonprofit's capacity to execute a $158M contract.

The $999,926 cost-plus-fixed-fee NASA contract for space R&D services is negligible relative to Lockheed Martin's revenue, but the cost-plus structure reduces risk and indicates ongoing NASA collaboration.

SIGA Technologies faces medium execution risk on its $626.5 million fixed-price contract; if development costs exceed estimates, margins could compress.

OUR RESCUE's $158.1 million HHS contract is a sole-source award with no competitive benchmark, creating concentration risk for HHS if the nonprofit fails to perform.

The VA medical disability exam contract for Leidos' QTC Medical Services is completed; any follow-on awards depend on VA budget continuity and potential policy changes.

SIGA Technologies' $626.5 million HHS/BARDA contract for smallpox antiviral development positions it for follow-on biodefense awards as NDAA priorities emphasize pandemic preparedness.

OUR RESCUE's $158.1 million HHS legal services contract has options that could increase total value to $244 million, providing upside if exercised.

Leidos' QTC Medical Services completed a $209.2 million VA contract; the company could win follow-on awards for medical disability exams in other regions or under new VA policies.

HHS/BARDA's $626.5 million award to SIGA Technologies for smallpox antiviral development underscores sustained government investment in biodefense, even outside pandemic emergencies.

Leidos' QTC Medical Services subsidiary completed a $209.2 million VA contract, demonstrating the VA's consistent demand for medical disability exams but offering no forward growth from this award.

HHS's sole-source $158.1 million award to nonprofit OUR RESCUE for legal support services indicates urgent need, but the time-and-materials structure and short base period create high risk.

{"entity" => "SIGA Technologies, Inc.", "reason" => "Secured $626.5 million HHS/BARDA contract with $447.2 million already outlayed; cost performance on fixed-price structure is critical.", "trigger" => "Quarterly earnings reports for cost performance updates; contract modifications or option exercises"}

{"entity" => "OUR RESCUE", "reason" => "Received $158.1 million sole-source HHS legal services contract; option exercise and re-compete decisions will determine revenue trajectory.", "trigger" => "Option exercise decision before February 2027; protests or competitive re-solicitations"}

{"entity" => "Leidos Holdings, Inc.", "reason" => "QTC Medical Services subsidiary completed $209.2 million VA contract; follow-on awards depend on VA budget and policy.", "trigger" => "VA re-compete announcements for medical disability examinations in Region 2 or other regions"}

{"entity" => "Lockheed Martin Corporation", "reason" => "Received $1 million NASA space R&D contract; immaterial but signals continued engagement.", "trigger" => "Follow-on NASA contracts or extensions beyond February 2027"}